{"_buckets": {"deposit": "9cab6ee4-7cb8-4151-82d6-11fbd9d544dc"}, "_deposit": {"created_by": 6, "id": "26875", "owners": [6], "pid": {"revision_id": 0, "type": "depid", "value": "26875"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00026875", "sets": ["9"]}, "author_link": ["119355", "119345", "119347", "119348", "119352", "119353", "119350", "119349", "119356", "119354", "119346", "119351"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2021-08-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "8", "bibliographicPageEnd": "1087", "bibliographicPageStart": "1081", "bibliographicVolumeNumber": "44", "bibliographic_titles": [{"bibliographic_title": "Biological and Pharmaceutical Bulletin"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Naldemedine (NAL), a peripherally acting μ-opioid receptor antagonist, is effective for opioid-induced constipation (OIC). However, diarrhea is the most common adverse event. We investigated the incidence of NAL-induced diarrhea in patients who started NAL at Nagasaki University Hospital between June 2017 and March 2019. Predictors of NAL-induced diarrhea were analyzed using a multivariate logistic regression model. Two hundred and forty-two patients were included in the present study, and NAL-induced diarrhea was observed in 17.8% (43 patients). The results of multiple logistic regression analyses identified the administration of opioid analgesics for 8 d or longer before the initiation of NAL (odds ratio (OR): 2.20, 95% confidence interval (95% CI): 1.04–4.64, p = 0.039), the combination of a laxative (OR: 2.22, 95%CI: 1.03–4.81, p = 0.042), and the combination of CYP3A4 inhibitors (strong/moderate) (OR: 2.80, 95%CI: 1.02–7.67, p = 0.045) as risk factors. Therefore, the development of diarrhea needs to be considered in patients with these risk factors. Furthermore, diarrhea may be controlled by the initiation of NAL within 7 d of opioid analgesics and, where possible, the discontinuation of or change in the combination of moderate or strong CYP3A4 inhibitors.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Biological and Pharmaceutical Bulletin, 44(8), pp. 1081-1087; 2021", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "日本薬学会 "}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1248/bpb.b21-00209", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2021 The Pharmaceutical Society of Japan"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0918-6158", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1347-5215", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Hashizume, Junya"}], "nameIdentifiers": [{"nameIdentifier": "119345", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shiojiri, Kyohei"}], "nameIdentifiers": [{"nameIdentifier": "119346", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ryu, Emi"}], "nameIdentifiers": [{"nameIdentifier": "119347", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawauchi, Yuki"}], "nameIdentifiers": [{"nameIdentifier": "119348", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hasegawa, Kyoko"}], "nameIdentifiers": [{"nameIdentifier": "119349", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ezaki, Nozomi"}], "nameIdentifiers": [{"nameIdentifier": "119350", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamashita, Haruna"}], "nameIdentifiers": [{"nameIdentifier": "119351", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishii, Koji"}], "nameIdentifiers": [{"nameIdentifier": "119352", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Harasawa, Hitomi"}], "nameIdentifiers": [{"nameIdentifier": "119353", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Tadahiro"}], "nameIdentifiers": [{"nameIdentifier": "119354", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sasaki, Hitoshi"}], "nameIdentifiers": [{"nameIdentifier": "119355", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kodama, Yukinobu"}], "nameIdentifiers": [{"nameIdentifier": "119356", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-11-19"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "BPBul44_1081.pdf", "filesize": [{"value": "372.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 372100.0, "url": {"label": "BPBul44_1081.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/26875/files/BPBul44_1081.pdf"}, "version_id": "5eece89f-14e2-4a26-811c-e339061434c6"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "naldemedine", "subitem_subject_scheme": "Other"}, {"subitem_subject": "diarrhea", "subitem_subject_scheme": "Other"}, {"subitem_subject": "predictive factor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "opioid analgesic", "subitem_subject_scheme": "Other"}, {"subitem_subject": "laxative", "subitem_subject_scheme": "Other"}, {"subitem_subject": "CYP3A4 inhibitor", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Analysis of Predictive Factors for Diarrhea after the Administration of Naldemedine", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Analysis of Predictive Factors for Diarrhea after the Administration of Naldemedine"}]}, "item_type_id": "2", "owner": "6", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/00041043", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-11-19"}, "publish_date": "2021-11-19", "publish_status": "0", "recid": "26875", "relation": {}, "relation_version_is_last": true, "title": ["Analysis of Predictive Factors for Diarrhea after the Administration of Naldemedine"], "weko_shared_id": -1}